Cargando…
A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report
Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650638/ https://www.ncbi.nlm.nih.gov/pubmed/36387184 http://dx.doi.org/10.3389/fonc.2022.1022290 |
_version_ | 1784828065841414144 |
---|---|
author | Shang, Yu Zhang, Yunkun Pan, Evenki Yang, Peng Xu, Lingling Sun, Jinghua |
author_facet | Shang, Yu Zhang, Yunkun Pan, Evenki Yang, Peng Xu, Lingling Sun, Jinghua |
author_sort | Shang, Yu |
collection | PubMed |
description | Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized by the presence of somatic CTNNB1 exon 3 mutations, leading to the activation of Wnt/β-catenin/Cox-2 signal pathway. Here, we firstly report that a refractory liver metastatic pancreatic SPN patient after the failure of multi-line chemotherapies benefited from the Cox-2 selective inhibitor (Celecoxib) based on CTNNB1 D32V mutation detected by next-generation sequencing (NGS), achieving a more than 22-month progression-free survival without any adverse events. Our case provides a potential treatment option for liver metastatic SPN patients with CTNNB1 mutations and highlights the application of NGS for the better treatment decision making. |
format | Online Article Text |
id | pubmed-9650638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96506382022-11-15 A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report Shang, Yu Zhang, Yunkun Pan, Evenki Yang, Peng Xu, Lingling Sun, Jinghua Front Oncol Oncology Solid pseudopapillary neoplasm (SPN) of the pancreas is rare relatively low-grade malignant neoplasm and metastasis rarely. Surgical resection is the primary treatment option for primary and metastatic lesions of SPN, and chemotherapy is often ineffective in non-operable SPNs. SPNs are characterized by the presence of somatic CTNNB1 exon 3 mutations, leading to the activation of Wnt/β-catenin/Cox-2 signal pathway. Here, we firstly report that a refractory liver metastatic pancreatic SPN patient after the failure of multi-line chemotherapies benefited from the Cox-2 selective inhibitor (Celecoxib) based on CTNNB1 D32V mutation detected by next-generation sequencing (NGS), achieving a more than 22-month progression-free survival without any adverse events. Our case provides a potential treatment option for liver metastatic SPN patients with CTNNB1 mutations and highlights the application of NGS for the better treatment decision making. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9650638/ /pubmed/36387184 http://dx.doi.org/10.3389/fonc.2022.1022290 Text en Copyright © 2022 Shang, Zhang, Pan, Yang, Xu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Shang, Yu Zhang, Yunkun Pan, Evenki Yang, Peng Xu, Lingling Sun, Jinghua A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title | A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title_full | A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title_fullStr | A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title_full_unstemmed | A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title_short | A refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored CTNNB1 mutation showed good response to celecoxib: A case report |
title_sort | refractory liver metastatic solid pseudopapillary neoplasm pancreas harbored ctnnb1 mutation showed good response to celecoxib: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650638/ https://www.ncbi.nlm.nih.gov/pubmed/36387184 http://dx.doi.org/10.3389/fonc.2022.1022290 |
work_keys_str_mv | AT shangyu arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT zhangyunkun arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT panevenki arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT yangpeng arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT xulingling arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT sunjinghua arefractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT shangyu refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT zhangyunkun refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT panevenki refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT yangpeng refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT xulingling refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport AT sunjinghua refractorylivermetastaticsolidpseudopapillaryneoplasmpancreasharboredctnnb1mutationshowedgoodresponsetocelecoxibacasereport |